Literature DB >> 2836219

Differential effects of oral trandolapril and enalapril on rat tissue angiotensin-converting enzyme.

C Chevillard1, N L Brown, M N Mathieu, F Laliberté, M Worcel.   

Abstract

Trandolapril (3-100 micrograms/kg) and enalapril (10-300 micrograms/kg) were administered orally to conscious rats. Angiotensin-converting enzyme (CE) activity was inhibited in serum, heart ventricle, renal inner cortex, lung, aorta, adrenal cortex and adrenal medulla, but not in the striatum. Inhibition was maximal at 2 h and with trandolapril was maintained for 24 h. Blood pressure and heart rate were not affected by either compound. Trandolapril was 6-10-fold more potent than enalapril. Differences between trandolapril and enalapril in CE inhibition observed in heart ventricle, adrenal cortex and medulla could be due to the presence of more than one type of CE or CE-like activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836219     DOI: 10.1016/0014-2999(88)90629-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice.

Authors:  Vincent Sauzeau; Mirjana Jerkic; José M López-Novoa; Xosé R Bustelo
Journal:  Mol Biol Cell       Date:  2007-01-03       Impact factor: 4.138

2.  Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene.

Authors:  Vincent Sauzeau; José M Carvajal-González; Adelaida S Riolobos; María A Sevilla; Mauricio Menacho-Márquez; Angel C Román; Antonio Abad; María J Montero; Pedro Fernández-Salguero; Xosé R Bustelo
Journal:  J Biol Chem       Date:  2010-11-29       Impact factor: 5.157

3.  Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction.

Authors:  Vincent Sauzeau; María A Sevilla; Juan V Rivas-Elena; Enrique de Alava; María J Montero; José M López-Novoa; Xosé R Bustelo
Journal:  Nat Med       Date:  2006-06-11       Impact factor: 53.440

4.  Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

Authors:  D W Cushman; F L Wang; W C Fung; G J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

5.  Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.

Authors:  E G Bevan; G T McInnes; J C Aldigier; J J Conte; J P Grunfeld; S J Harper; B H Meyer; N Pauly; R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

Review 6.  Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors?

Authors:  F Zannad
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.

Authors:  Jessica C Song; C Michael White
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 5.577

9.  Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.

Authors:  David G Levitt; Rik C Schoemaker
Journal:  BMC Clin Pharmacol       Date:  2006-01-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.